within Pharmacolibrary.Drugs.ATC.C;

model C08CA10
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.062,
    Cl             = 0.0007,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.033,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600,            
    Vdp             = 0.234,
    k12             = 62,
    k21             = 62
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08CA10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nilvadipine is a dihydropyridine calcium channel blocker used for the treatment of hypertension and angina. It works by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle. Nilvadipine is used widely in Japan and some other countries but is not approved for clinical use in the United States or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Terakawa, M, et al., &amp; Noguchi, H (1987). Pharmacokinetics of nilvadipine in healthy volunteers. <i>Journal of clinical pharmacology</i> 27(2) 111–117. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1987.tb02170.x&quot;>10.1002/j.1552-4604.1987.tb02170.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3680562/&quot;>https://pubmed.ncbi.nlm.nih.gov/3680562</a></p></li><li><p>Cheung, WK, et al., &amp; Silber, BM (1988). Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers. <i>International journal of clinical pharmacology research</i> 8(5) 299–305. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3229870/&quot;>https://pubmed.ncbi.nlm.nih.gov/3229870</a></p></li><li><p>Tokuma, Y, et al., &amp; Noguchi, H (1988). Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 18(1) 21–28. DOI:<a href=&quot;https://doi.org/10.3109/00498258809055133&quot;>10.3109/00498258809055133</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3354229/&quot;>https://pubmed.ncbi.nlm.nih.gov/3354229</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08CA10;
